Pre−clinical studies have demonstrated synergistic anti−tumour effects of chemotherapy (CT) and zoledronic acid (ZOL). Within the AZURE trial, designed to determine whether the addition of ZOL to neoadjuvant therapy improves disease outcomes, a subgroup received neoadjuvant CT. We report a retrospective evaluation comparing pathological response in the primary tumour between treatment groups.

In total, 205 patients received neoadjuvant CT+/−ZOL (CT+ZOL, n=102; CT, n=103). The primary end point was pathologically assessed residual invasive tumour size (RITS) at surgery. Secondary end points were pathological complete response (pCR) rate and axillary nodal involvement. Following review of surgical pathology reports (n=195), outcome differences between groups were assessed adjusting for potential response modifiers.

Baseline characteristics and CT treatments were similar. In multivariate analysis, allowing for biological and clinical factors known to influence tumour response, the adjusted mean RITS in CT and CT+ZOL groups were 27.4 and 15.5 mm, respectively, giving a difference in means of 12 mm (95% confidence interval: 3.5−20.4 mm; P=0.006). The pCR rate was 6.9% in the CT group and 11.7% in the CT+ZOL group (P=0.146).There was no difference in axillary nodal involvement (P=0.6315).

These data suggest a possible direct anti−tumour effect of ZOL in combination with CT, warranting formal evaluation in prospective studies.British Journal of Cancer advance online publication, 16 March 2010; doi:10.1038/sj.bjc.6605604 www.bjcancer.com.

PMID: 20234364 [PubMed − as supplied by publisher] Source: National Library of Medicine.